RF
CORT icon

Rossby Financial’s Corcept Therapeutics CORT Stock Holding History

Rossby Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.87K Buy
79
+9
+13% +$543 ﹤0.01% 1309
2026
Q1 		$2.94K Buy
70
+32
+84% +$1.2K ﹤0.01% 1684
2025
Q4 		$1.32K Buy
38
+6
+19% +$471 ﹤0.01% 1476
2025
Q3 		$2.7K Buy
32
+11
+52% +$796 ﹤0.01% 1087
2025
Q2 		$1.54K Buy
+21
New +$1.52K ﹤0.01% 1085

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rossby Financial's CORT Position: Q2 2026 in Review

Rossby Financial increased its Corcept Therapeutics (CORT) stake by 13% in Q2 2026, buying an estimated $543 and bringing the position to 79 shares worth $6.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

Rossby Financial first reported a position in CORT in Q2 2025 and has held it in 5 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Rossby Financial held 79 shares of Corcept Therapeutics worth $6.87K as of Q2 2026.
  • Rossby Financial bought 9 Corcept Therapeutics shares in Q2 2026, an estimated $543.
  • Corcept Therapeutics made up ﹤0.01% of Rossby Financial's portfolio in Q2 2026, its #1309 holding.
  • Rossby Financial first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Rossby Financial's 13F filing for Q2 2026, filed 4 Aug 2026.